Procedure | Phase 1 | Phase 2 (long-term follow-up) | |||||||
Screening | Baseline | 6 weeks | 3 months and every 6 months | 1st year | 2nd year | 3rd year | 4th year | 5th year | |
Eligibility assessment | X | X | |||||||
Informed consent | X | ||||||||
Demographic data (DOB, sex, ethnicity, height and weight) | X | ||||||||
Smoking and diet | X | ||||||||
Relevant clinical history—especially determining arrhythmia aetiology | X | ||||||||
Evaluation of left ventricular systolic function via echocardiography, CMRI or radionucleotide imaging | X | ||||||||
Record current medications | X | ||||||||
Lying and standing BP | X | ||||||||
Routine blood tests: U&E (sodium, potassium, urea and creatinine), GFR, glucose, and HbA1c Vascular biomarkers: high-sensitivity troponin, NT-pro BNP, CRP, high-sensitivity CRP, interleukin-6 | X | ||||||||
Magnetocardiogram | X | ||||||||
ICD implantation | X | ||||||||
Routine ICD interrogation | X | X | X | X | X | X | X |
BNP, brain natriuretic peptide; BP, blood pressure; CMRI, cardiac MRI; CRP, C reactive protein; DOB, date of birth; GFR, glomerular filtration rate; hbA1c, haemoglobin A1c; ICD, implantable cardioverter defibrillator.